Skip to main content

Table 2 Adherence to PMTCT guidelines, stratified by ART eligibility

From: Delays, interruptions, and losses from prevention of mother-to-child transmission of HIV services during antenatal care in Johannesburg, South Africa: a cohort analysis

 

All women

CD4 ≤ 350

CD4 > 350

 

158

72

67

1. First ANC visit prior to 20 weeks gestation

No record of gestational age, last menstrual period, or expected date of delivery

8 (5%)

4 (6%)

4 (6%)

<20 weeks gestation at first ANC

39 (26%)

15 (21%)

20 (30%)

2. Initiate CD4 testing at first ANC visit

CD4 tests results from first ANC found

139 (88%)

72

67

WHO clinical stage found

86 (54%)

43 (60%)

32 (48%)

3. Initiate AZT prophylaxis when first eligible (at least 14 weeks gestation and Hb ≥ 8 g/dl)

>13 weeks gestation at first visit

141 (89%)

65 (90%)

58 (87%)

Hb ≥ 8 g/dl at first visit

132 (84%)

56 (78%)

60 (90%)

Known eligible for AZT

118 (75%)

51 (72%)

52 (78%)

Received AZT at first visit, if eligible

81 (69%)

37 (73%)

32 (62%)

4. Receive CD4 count results

Have CD4 results visit recorded

53 (38%)

36 (50%)

17 (25%)

Made a return visit to clinic <3 weeks

38 (24%)

24 (33%)

13 (19%)

Made a return visit to within 60 days

96 (69%)

47 (65%)

49 (73%)

Median days to CD4 results received (n = 106)

28 (IQR: 8–34)

19 (IQR: 8–29)

29 (IQR: 8–36)

5. Initiate ART within 30 days of first ANC or receive 60-day uninterrupted supply of AZT

Initiate ART within 30 days of first ANC

N/A/1

2 (3%)

N/A

Initiated ART within 60 days of first ANC

N/A

15 (21%)

N/A

Median days to ART initiation (n = 15)

N/A

47 (IQR: 37–57)

N/A

Weeks gestation at ART initiation (n = 15)

N/A

27 (IQR: 24–33)

N/A

Receive 60-day uninterrupted supply of AZT

N/A

N/A

10 (15%)

Received 60-day supply of AZT within 60 days

N/A

N/A

20 (30%)

Median days from first AZT to 2nd AZT (n = 20)

N/A

N/A

31 (IQR: 29–36)

  1. /1 N/A = not applicable.